Better overall survival with checkpoint inhibitor: cervical cancer trial

Results from the KEYNOTE-826 trial in women with metastatic disease

The checkpoint inhibitor, pembrolizumab, increases overall survival by 36% in patients with persistent, recurrent or metastatic cervical cancer, according to trial results.

woman's hand. IV drip.

The results of the KEYNOTE-826 trial carried out at 151 centres in 19 countries were announced at the European Society for Medical Oncology Congress in September and simultaneously published in The New England Journal of Medicine.

The double-blind phase III study of 617 patients showed a two-year survival